Garda Therapeutics

Garda Therapeutics is an emerging pharmaceutical company dedicated to driving innovation in the pharmaceutical industry by maximizing opportunities with mid-sized specialty assets. The firm focuses on procuring proprietary, "growable" therapeutic assets through product or company acquisitions and attractive licensing opportunities. Their business model centers on strategic acquisitions of established drug products rather than traditional drug discovery and development, allowing them to leverage existing regulatory approvals and market presence while applying operational expertise to drive growth.

The company was established with a mission to identify and scale therapeutic assets that have demonstrated clinical value but require enhanced commercial execution. While specific founding dates and detailed founder information are not publicly disclosed, the management team brings over 175 years of collective experience in life sciences, with a strong track record in successfully growing underutilized therapeutics.

Garda Therapeutics targets potential assets primarily in oncology, including both hematology and solid tumors. Notable acquisitions include FARYDAK® from Novartis in 2019 and COPIKTRA® from Verastem in 2020. The company also highlights past successful product acquisitions and value creation with assets such as ENTOCORT EC®, LOTRONEX®, and PROLEUKIN®. Recently, Garda Therapeutics entered into an agreement to acquire Assertio Holdings.

The leadership team at Garda Therapeutics comprises highly experienced professionals in the life sciences sector. Joseph Limber serves as Chief Executive Officer, bringing over 35 years of experience, including leadership roles at Secura Bio, Genoptix, and Prometheus Laboratories. Brett Lund, JD, MBA, is the President & Chief Legal Officer, with over 25 years of life science experience, previously at Secura Bio and Genoptix. William Davis is the Executive Vice President, Commercial, with extensive experience in global marketing and sales for oncology brands. Jamie Sulley, PhD, MPH, is the SVP Global Regulatory Affairs, possessing over 35 years of experience in biotech and pharmaceuticals. Beth Kriegel, CPA, serves as Chief Financial Officer, and Steven Hildemann, MD, PhD, is the Chief Medical Officer.